1. Docetaxel/gefitinib
   , 2016, Reactions Weekly CrossRef
2. Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
   Deborah A. Belchis et al, 2016, Oncotarget CrossRef
3. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
   Surya K. Tripathi et al, 2020, Medicinal Research Reviews CrossRef
4. Therapeutic approaches for T790M mutation positive non-small-cell lung cancer
   Ilaria Attili et al, 2018, Expert Review of Anticancer Therapy CrossRef
5. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
   Chike Osude et al, 2022, Cells CrossRef
6. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports
   Yue Zeng et al, 2022, Frontiers in Pharmacology CrossRef